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Open acceAbstract High-grade conventional osteosarcoma is a malignant tumour predominantly
affecting adolescents and, despite multimodal intensive therapy, lethal for one third of the
patients. Although there is currently detailed knowledge of normal skeletal development, this
has not been integrated into research on the genesis of osteosarcoma. Recently we showed that
the canonical Wnt pathway is not active in osteosarcoma and that its reactivation is disadvan-
tageous to osteosarcoma cells. Since Wnt is regulating normal skeletogenesis together with
other pathways, here we report on the activities of the bone morphogenic protein (BMP),
the transforming growth factor beta (TGFb) and the hedgehog (Hh) pathways in osteosar-
coma. Human osteosarcoma samples (n = 210), benign bone tumours of osteoblastic lineage
called osteoblastoma (n = 25) and osteosarcoma cell lines (n = 19) were examined. For path-
way activity luciferase transcriptional reporter assays and gene and protein expression analy-
ses were performed. Immunohistochemical analysis of phosphorylated Smad1 and Smad2, the
intracellular effectors of BMP and TGFb, respectively, showed nuclear expression of both
proteins in 70% of the osteosarcoma samples at levels comparable to osteoblastoma. Interest-
ingly cases with lower expression showed signiﬁcantly worse disease free survival. This may
imply that drugs restoring impaired signalling pathways in osteosarcoma might change the
tumour’s aggressive clinical course, however targeted pathway modulation in vitro did not
affect cell proliferation.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. 18
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High-grade conventional osteosarcoma is an aggres-
sive malignant bone tumour preferentially found in
young adults.1 The 5-year survival rate of osteosarcoma
patients has improved up to about 60%,2 however for
the patients who do not respond to the presently applied
chemotherapy alternative treatment regimens are
required. Most conventional osteosarcomas are located
at the metaphysis of the long bones adjacent to the
growth plate where elongation of the bones, especially
at puberty, is most active. Therefore we hypothesised
that physiological regulation of signal transduction
involved in normal skeletal diﬀerentiation is impaired
in osteosarcoma. Restoring the diﬀerentiation might
change the aggressive osteosarcoma into a less aggres-
sive, more diﬀerentiated tumour.3
Bone is continuously remodelled by a balanced pro-
cess of bone formation by osteoblasts and bone resorp-
tion by osteoclasts. During this process several major
signalling pathways such as canonical wingless (Wnt),
bone morphogenic protein (BMP), transforming growth
factor beta (TGFb) and hedgehog (Hh) regulate the dif-
ferentiation of mesenchymal stem cells (MSCs). This
indicates that alteration of one or more of these path-
ways could aﬀect the normal diﬀerentiation and might
cause disease.4–6 Previously we showed that in contrary
to other reports7 the Wnt pathway is inactive in osteo-
sarcoma and that its reactivation can inhibit osteosar-
coma cell proliferation and stimulate diﬀerentiation.8
TGFb is found to be abundantly present in normal bone
matrix9 and the pathway plays a prominent role in many
diﬀerent tumour types.10 As a result of BMP and TGFb
activity, Smad1 and Smad2 respectively become phos-
phorylated and are translocated to the nucleus where
they activate speciﬁc genes.11 In human bone, the hedge-
hog pathway (Hh) tightly regulates growth and diﬀeren-
tiation.12,13 Hh starts a cascade which results in
stabilising GLI, which subsequently activates down-
stream target genes, especially itself and the Hh repres-
sor PTCH.
In this study we investigated the activities of the
BMP/TGFb and Hh pathways in osteosarcoma. To
consider the relation between impaired diﬀerentiation
and malignant transformation we compared the activity
levels in osteosarcoma to those found in osteoblastoma.
The latter is a benign bone tumour with fully terminal
osteoblastic diﬀerentiation that interestingly never pro-
gress to a malignant phenotype. In addition, the eﬀect
of pathway modulation on osteosarcoma cells was
assayed by investigating cell proliferation and migra-
tion. We show that the TGFb/BMP pathways are active
in most osteosarcomas and that a low activity of TGFb
signalling signiﬁcantly predicts poor survival of the
patients. Furthermore the Hh pathway shows various
activity levels in osteosarcoma and its inhibition bycyclopamine inhibits proliferation of osteosarcoma cells.
However this is independent of Hh activity and could
therefore be considered as an oﬀ-target eﬀect.
2. Materials and methods
2.1. Clinical samples
Formalin-ﬁxed, paraﬃn-embedded (FFPE) tissues
were retrospectively collected from 127 patients diag-
nosed with high-grade primary osteosarcoma selected
for osteosarcoma trials (according to EURAMOS1
and EORTC Protocol Nos 80831, 80861 and 80931),
with a total of 210 samples. In addition FFPE tissues
from 25 osteoblastomas were collected. Histological
details and clinical follow up data are depicted in Sup-
plementary Table 1. All tissue samples were handled in
a coded fashion according to Dutch national ethical
guidelines (Code for Proper Secondary Use of Human
Tissue, Dutch Federation of Medical Scientiﬁc
Societies).
2.2. Immunohistochemical staining (IHC)
Tissue cores from tumour areas were taken to con-
struct two tissue arrays (TMAs) as previously
described.4 Slides were stained with pSmad1 (1:50 dilu-
tion) and pSmad2 (1:200 dilution) antibodies (Cell
Signalling, Danvers, United States of America (USA))
and independently evaluated by two observers
(P.C.W.H. and C.A.), scoring nuclear staining for their
intensity (0 = no, 1 = weak, 2 = moderate, 3 = strong)
and the percentage (1 6 25%, 2 = 25–50%, 3 = 50–
75%, 4P 75%) of positive neoplastic cells. The total
score of a sample was calculated as the average sum of
intensity and percentage of all its cores, ranging from
0 to 7.
2.3. Genome-wide gene expression proﬁling and data
analysis
Genome-wide expression proﬁling was performed on
pre-treatment diagnostic frozen biopsies of 53 high-
grade osteosarcoma patients from the EuroBoNet con-
sortium,14 of which most were not available on the
aforementioned paraﬃn tissue arrays, and on 12 MSCs
cultures. RNA isolation, cDNA synthesis, cRNA ampli-
ﬁcation, Illumina Human-6 v2.0 Expression BeadChip
hybridisation, qPCR validation and microarray data
analysis were performed as previously described.14
MIAME-compliant data have been deposited in the
GEO database (www.ncbi.nlm.nih.gov/geo/, accession
numbers GSE21257 for biopsies, GSE28974 for MSCs).
Pathway analysis was performed on Wnt, BMP, TGFb
and Hh pathways using the Ingenuity Pathways Analy-
sis (Ingenuity Systems, www.ingenuity.com).
A.B. Mohseny et al. / European Journal of Cancer 48 (2012) 3429–3438 34312.4. Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
RNA isolation, cDNA reactions and qRT-PCR were
performed as previously described.4 The following prim-
ers for PTCH1 andGLI1 were used respectively: forward
50 CCACGACAAAGCCGACTACAT 30, reverse 50
GCTGCAGATGGTCCTTACTTTTTC 30 and forward
50 TGCAGTAAAGCCTTCAGCAATG 30, reverse 50
TTTTCGCAGCGAGCTAGGAT 30. The CT values
were normalised using the 2DDCT method.15
2.5. Cell culture and reagents
Culturing conditions of the cell lines used are
depicted in Supplementary Table 2. The human osteo-
sarcoma cell lines as well as other control cell lines were
purchased from ATCC or obtained from EuroBoNet
partners.16 After performing multiple dose–response
experiments for all drugs, the following dosages were
used to speciﬁcally inhibit or stimulate the pathways.
TGFb activity was inhibited by 10 lM SB-431542
(Tocris Bioscience, Bristol, United Kingdom (UK))
and stimulated by 5 ng/ml TGFb3 (Sigma, Munich,
Germany). BMP activity was inhibited by 100 nM
LDN-193189 (Stemgent Inc., San Diego, CA, USA)
and stimulated by 300 ng/ml BMP4 (R&D systems,
Minneapolis, USA). Hh activity was inhibited by
10 lM KAAD-cyclopamine (Toronto Research Chemi-
cals Inc.) and 4 lM arsenic trioxide (Sigma) and stimu-
lated by adding 300 ng/ml recombinant hedgehog (R&D
systems). Mouse myoblast cells C2C12, human liver car-
cinoma cells HepG2 and human pancreatic carcinoma
cells PANC1 were used as positive controls for BMP,
TGFb and Hh activities, respectively. Human MSCs
were not used as positive controls because of technical
diﬃculties leading to unacceptably low transfection
eﬃciency.Fig. 1. Pathway analysis. Genome wide gene-expression analysis on a
developmental pathways are deregulated in osteosarcoma as compared to m
is calculated by the number of molecules in a given pathway that meets
divided by total number of molecules that are annotated on the microarra2.6. Plasmids
The BMP-responsive element (BRE)-luciferase con-
struct and theTGFbpathway responsive plasmid contain-
ing a (CAGA)12-luciferase reporter, have been described
previously.17,18 The Hh pathway reporter Gli-luciferase
plasmid was a kind gift from Dr. P. Beachy (Stanford,
CA, USA).19 pRL-CAGGS vector containing renilla
luciferase under a constitutive CAGGS promoter was
used for quantifying the transfection eﬃciency (Promega,
Leiden, The Netherlands). A Gli1-SiRNA-SMART pool
(Dharmacon, Chicago, USA) was used to speciﬁcally
down-regulate the Hh activity by inhibiting GLI-1.
2.7. Proliferation assay
The number of viable cells was determined by using a
Cell Titer-96 Aqueous One Solution Cell Proliferation
Assay (MTS) from Promega according to the manufac-
turer’s instructions and measuring each condition in
triplicate.
2.8. Transient transfection and luciferase assay
Cells were seeded at a density of 5000 cells per well in
96-well ﬂat-bottom plates. Next day, 100 ll transfection
complex was prepared with 1.95 lg of each reporter plas-
mid and 0.05 lg of pRL-CAGGS. 5 ll of the mix was
added per well using Fugene HD transfection reagent
(Roche, Mannheim, Germany) according to the manu-
facturer’s protocol. After 24 h the medium was replaced
by medium supplemented with drugs as indicated or
DMSO as vehicle. After 24 h incubation, cells were har-
vested and luciferase activity was measured with a Victor
3 Multilabel Counter 1420-042 (Perkin Elmer, MA,
USA). The ratio of ﬁreﬂy/renilla ﬂuorescence was calcu-
lated to normalise reporter activity. Three independent
transfections were performed, each in triplicate.subset of osteosarcoma pre-treatment cases (n = 53) shows that the
esenchymal stem cells (MSCs) (n = 12, bars and upper scale). The ratio
cut-oﬀ criteria (false discovery rate (FDR)-adjusted p-values < 0.05),
y and make up that speciﬁc pathway (lines and lower scale).
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Cells were cultured in 6-well plates until 90% conﬂu-
ence and starved overnight in 0.5% FCS medium. Next
day cells were scratched using a sterile 200 ll pipette tip
and medium containing 1.5 ml of each drug was added.2.10. Statistical analysis
Statistical analyses were performed using SPSS
software version 16.0. Results are presented as mean-Fig. 2. The bone morphogenic protein (BMP)/the transforming growth fac
Pie chart showing the sample types of the osteosarcoma tissues used. (B) Rep
pSMAD1 and pSMAD2 are expressed in all osteoblastoma (OB) cases whi
expression. (C) Bar graph depicting the percentages of the scores (0–7) for p
found in OB was 3 for which the threshold of positivity for these proteins w
pre-treatment osteosarcoma cases with low and high (threshold score = 3)
pSmad2 nuclear expression show worse overall survival which is statisticas ± SEM. A p value of less than 0.05 was considered as
signiﬁcant.3. Results
3.1. Involvement of developmental pathways in
osteosarcoma
Pathway analysis performed by using the Ingenuity
Pathway Analysis (IPA) software on a cohort of osteo-
sarcoma pre-treatment cases (n = 53) showed that thetor beta (TGFb) pathway activities by protein expression analyses. (A)
resentative immunohistochemical staining (IHC) pictures showing that
le in osteosarcoma (OS) a subgroup was found with very low or absent
Smad1 and pSmad2 protein expression in OS and OB. The lowest score
as set at 3. (D) Kaplan–Meier survival curves are shown for comparing
nuclear pSmad1 and pSmad2 expression. Cases with low pSmad1 and
lly signiﬁcant for pSmad2 expression (p = 0.008).
Fig. 3. The hedgehog (Hh) pathway activity by gene expression analysis. (A) Expression levels of the PTCH1 and GLI1 genes measured by
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in 19 osteosarcoma cell lines are shown. Levels were normalised by the
2DDCt method. Each dot represents one cell line indicating a wide variation of expression levels in osteosarcoma cell lines. (B) Spearman’s
correlation analysis showing signiﬁcant correlation of PTCH1 and GLI1 expression determined by the qRT-PCR and the whole genomic
expression array analysis of these 19 cell lines (unpublished data). This validates the expression array results and conﬁrms the wide spread of
expression levels of PTCH1 and GLI1. (C) Whole genomic expression array data of the 53 pre-treatment patient samples again show variability of
the gene expression levels of the Hh key genes PTCH1 and GLI1.
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Hh are signiﬁcantly deregulated in osteosarcoma as
compared to the presumed progenitor cells of osteosar-
coma, i.e. normal MSCs (Fig. 1). Although this analysis
does not show whether the pathways are up- or down-
regulated as compared to their activities in MSCs, it
indicated that Wnt, TGFb and BMP signalling path-
ways may be involved in osteosarcoma pathogenesis
warranting further investigation of the activity by func-
tional studies.3.2. BMP/TGFb pathways are active in most
osteosarcoma samples and TGFb signalling is
signiﬁcantly associated with prognosis
To investigate the activity of the BMP/TGFb path-
ways in clinical cases (Fig. 2A), nuclear protein expres-
sion of phosphorylated (p) Smad1 (BMP) and pSmad2
(TGFb) was assayed by IHC as shown in Fig. 2B.
pSmad1 and pSmad2 were both expressed in most sam-
ples, 85.4% (140/164) and 85.2% (127/149), respectively
(Fig. 2C). To investigate whether incomplete osteogenic
diﬀerentiation would be related to aggressive behaviour,
expression levels were compared to those found in oste-
oblastoma. As both were also highly expressed in osteo-
blastomas 100% (25/25) a score threshold of 3 (lowest
score in osteoblastoma) was set to indicate low activity
of the pathways (Fig. 2C). Using this threshold,
pre-treatment cases (biopsies) with low pSmad1 and
pSmad2 expression showed lower overall survival,
p = 0,1 and p = 0008, respectively (Fig. 2D). For this
analysis only pre-treatment samples were used since che-
motherapy may aﬀect Smad phosphorylation. The dif-
ferences in survival only appear after 50 months
conﬁrming that patients with metastatic disease at
diagnosis have poor survival regardless of the Smad
expression.3.3. Hh pathway activity is highly diverse among
osteosarcoma samples and cell lines
The Hh activity, measured by quantifying the gene
expression levels of key downstream genes PTCH1
and GLI1, was highly variable among cell lines
(Fig. 3A), however the values correlated signiﬁcantly
to the data found by whole genomic expression analysis
(Fig. 3B). After this validation the high variability in
PTCH1 and GLI1 expression in patient samples
(Fig. 3C) was considered as evident and did not corre-
late with clinical behaviour.3.4. Functional assays conﬁrm the activity of the
pathways
The luciferase reporter assays showed functionally
active BMP (Fig. 4A) TGFb (Fig. 4B) and Hh
(Fig. 4C) pathways in most cell lines. The OSA cell line
showed the highest (intrinsic) activity levels for these
three pathways. The MG-63 cell lines did not show
any Hh activity and stimulation of the pathway did
not increase the activity level (Fig. 4C). Except for this,
all three pathways could be either stimulated or inhib-
ited by using the appropriate drugs.3.5. Pathway modulation does not inhibit proliferation or
migration of the cells
Pathway modulation was performed by treating cells
transfected with luciferase reporter constructs with the
indicated drugs. Functional reactivity of all pathways
was conﬁrmed by showing increase or decrease of lucif-
erase activity upon treatment (Fig. 4). Except for cyclop-
amine, treatments did not signiﬁcantly aﬀect the
proliferation (Fig. 5A and B) or the migration rates of
the cells (Fig. 5C). To further investigate whether the
Fig. 4. Functional pathway activity and modulation. (A) Graph
depicts bone morphogenic protein (BMP) activity of the osteosarcoma
cell lines measured by a luciferase reporter system. In all cell lines
pathway activity could be inhibited by adding 100 nM of LDN-193189
and stimulated by using 300 ng/ml of BMP4. (B) As (A) however here
the transforming growth factor beta (TGFb) pathway was inhibited by
adding 10 lM SB-431542 and stimulated by adding 5 ng/ml TGFb3,
showing altered activities. (C) The hedgehog (Hh) pathway activity
was not found in all osteosarcoma cell lines at levels comparable to the
control PANC1 cell line. The OSA cells show high Hh activity
consistent with the GLI1 ampliﬁcation observed in this cell line and its
primary tumour40 while there is no activity in MG-63 cells. In all other
lines the Hh activity was successfully inhibited by the addition of
10 lM cyclopamine and stimulated by adding 300 ng/ml hedgehog.
Fig. 5. Eﬀects of pathway modulation on proliferation and migration.
(A) Line graphs represent proliferation of the MG-63 cells after
pathway modulation by the drugs as indicated or untreated (DMSO).
The graph is representative for all cell lines, MG-63 was chosen to show
since in this cell line no hedgehog (Hh) activity was present as shown in
Fig. 3. Except for cyclopamine there was no signiﬁcant eﬀect on cell
proliferation up to 120 h after treatment. (B) Pictures of the Saos-2 cell
line and representative for the other cell lines showing decreased cell
numbers after treatment with cyclopamine indicating decreased cell
proliferation as shown in (A). (C) Pictures of cell cultures showing that
modulation of the bone morphogenic protein (BMP)/the transforming
growth factor beta (TGFb) pathways by the drugs as indicated did not
aﬀect the migration of the cells. Pictures were taken from the HOS cell
line and are representative for all cell lines.
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Hh inhibition, the Hh pathway was more speciﬁcally
inhibited in OSA cell line – which showed the highest
activity of Hh – by using a Gli1-siRNA SMARTpool
and arsenic trioxide. The pathway activity signiﬁcantly
Fig. 6. Speciﬁc hedgehog (Hh) repression. Experiments assaying more speciﬁc inhibition of the Hh pathway by using a Gli1-SiRNA construct and
arsenic trioxide (ATO) in OSA cells which have the highest Hh activity. While the pathway activity was lowered to about 10% conﬁrmed by the
luciferase reporter assay (A) and the expression of the transcripts PTCH1 and GLI1 (B), there was no eﬀect on the proliferation of the cells (C).
A.B. Mohseny et al. / European Journal of Cancer 48 (2012) 3429–3438 3435decreased measured by the luciferase reporter (Fig. 6A)
and gene expression levels of PTCH1 and GLI1
(Fig. 6B), however proliferation was not aﬀected
(Fig. 6C).
4. Discussion
Reports from international collaborative studies have
shed light into osteosarcoma aetiology and pathogene-
sis.4,5,8,14,20 Impaired diﬀerentiation of a mutated,
genomically instable MSC may contribute to osteosar-
coma-genesis.5,8,21,22 Previously we conﬁrmed this by
showing aberrant Wnt pathway activity in osteosar-
coma.8 In this study we analysed other important path-
ways in bone homeostasis, i.e. the BMP/TGFb and Hh
pathways (Fig. 7).
Next to the essential roles of the BMP signalling in
normal skeletal development, studies have indicated its
involvement in promoting metastasis.23,24 However
research addressing the functionality of this pathway spe-
ciﬁcally in osteosarcoma, is limited.25,26 As BMPs can
induce ectopic bone formation27 and osteosarcoma is
characterised by osteoid formation, it is reasonable to
ﬁnd active BMP signalling in this tumour. Consistent
with this ﬁnding, expression of BMP components was
found in several benign and malignant bone
tumours,28,29 indicating that activation of the BMP path-
way might not be related to malignant transformation.
Here we conﬁrm this by showing that pSmad 1 is
expressed in the nuclei of most osteosarcoma cells indi-
cating true activity of the pathway. Moreover by using
luciferase reporters we demonstrate that the pathway is
active and can be successfully modulated. This, however,
does not aﬀect the osteosarcoma cells’ proliferation.
The role of TGFb in MSC diﬀerentiation is not fully
clear. It is generally thought that TGFb increases bone
formation by promoting the early stages of diﬀerentia-
tion,30 but inhibits mineralisation at later stage.31 Stud-ies in cancer have revealed a dual role of the TGFb
pathway as well, acting as a tumour suppressor in the
initiation phase while promoting cancer progression in
later phases.10 Previously TGFb was reported to stimu-
late osteosarcoma cell proliferation32 and was related to
aggressive behaviour and poor outcome in osteosar-
coma patients.33,34 However these studies only report
on an association with the presence of ligands, which
is not always indicative of functional pathway activity.
Interestingly in this study stimulation or inhibition of
the pathway did not aﬀect osteosarcoma cells’ prolifera-
tion. An explanation for this may be that in the previous
report32 cells were starved prior to stimulation by TGFb
rather indicating the normal reaction of starved cells to
a growth factor than an osteosarcoma speciﬁc growth
stimulation. In this study high pSmad2 expression in
pre-treatment samples signiﬁcantly correlated with bet-
ter survival (Fig. 2). This might be related to recent dis-
coveries showing immune-stimulating activity of the
TGFb pathway35 which is in line with our recent results
showing a signiﬁcant role for the innate immune system
in osteosarcoma’s clinical course.14,36
Upregulation of Hh signalling has been implicated in
cancer, especially in pancreas and basal cell carcinoma,
but reports of Hh in sarcoma are scarce.37 The only
study investigating the role of Hh in osteosarcoma was
performed on limited number of cases38 and showed
that Hh inhibition by cyclopamine inhibits osteosar-
coma cells’ proliferation. Accordingly SMO was indi-
cated as a new therapeutical target for osteosarcoma.
Our results show high variability of Hh activity mea-
sured by the expression levels of PTCH1 and GLI1 in
cell lines (Fig. 3A) and clinical samples (Fig. 3C) which
might be a result of the tissue heterogeneity found in
osteosarcoma. Functional activity measured by a Hh
reporter in osteosarcoma cell lines demonstrated high
Hh activity only in OSA cell line, which could be attrib-
uted to an ampliﬁcation at 12q, including the GLI1
Fig. 7. Mesenchymal stem cell diﬀerentiation and osteosarcoma development. Schematic representation of several signal transduction pathways
which play a role in skeletogenesis. The lines at the bottom depict the activity levels of these pathways during stem cell diﬀerentiation towards
diﬀerent lineages. Deregulation of one or more of these pathways may be involved in osteosarcoma-genesis.
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and CDK4 genes which are known, often ampliﬁed,
oncogenes in osteosarcoma, indicating that this ampliﬁ-
cation may not be targeted at GLI1. The growth inhib-
iting eﬀect of cyclopamine which we conﬁrmed here, can
be considered as an oﬀ-target, toxic eﬀect for a number
of reasons. Firstly, by knocking down the GLI1 tran-
scription factor and speciﬁcally decreasing Hh activity
(shown by luciferase reporter and expression of target
genes, Fig. 6) no inhibition of proliferation was detected.
Secondly even though MG63 cells do not have any
intrinsic Hh activity (Fig. 4), cyclopamine treatment
resulted in decreased proliferation in these cells. More-
over after lowering the cyclopamine dosage, the prolifer-
ation inhibitory eﬀect was lost in all 19 osteosarcoma
cell lines (data not shown).
In conclusion, the current study clariﬁes the activity
states of developmental pathways in osteosarcoma. We
show that BMP/TGFb signalling pathways are func-
tionally active in the majority of osteosarcoma cases
tested by the expression of phosphorylated Smads and
in osteosarcoma cell lines tested by luciferase reporter
systems. Interestingly a subgroup of osteosarcoma
patients with low pSmad2 expression showed signiﬁ-
cantly worse disease speciﬁc survival, which might indi-
cate a diﬀerent role of the TGFb pathway in regulation
of anti-tumour immunity. Furthermore, our ﬁnding thatcyclopamine inhibitory eﬀect is independent of Hh activ-
ity explains the conﬂicting data in the literature on Hh
targeted therapy in numerous cancers.
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